Urinary PGE-MUM as a Marker for Ulcerative Colitis Activity
Observational · No treatment assigned · 1 site · Assiut University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Ulcerative Colitis (UC). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Adult patients aged ≥18 years
- Confirmed diagnosis of Ulcerative Colitis based on clinical, endoscopic, and histopathological criteria
- Active disease (Mayo Endoscopic Score 2-3, Clinical Activity Index ≥4) OR remission (Mayo Endoscopic Score 0-1, Clinical Activity Index ≤3)
Plus 1 more requirement(s). There are also 9 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 114 participants are expected to take part.
- Start date: 2026-08-01 (planned).
- Main results expected around 2027-01-31 (estimate from the record).
- 1 study site listed in Egypt.
Main thing being measured
- Urinary PGE-MUM Levels Discriminates Disease Activity in UC (At the time of enrollment (single visit, cross-sectional assessment))
In the researchers’ words
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires regular monitoring of disease activity. Currently, assessment depends on invasive colonoscopy or clinical scores that may not accurately reflect intestinal inflammation.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Ulcerative Colitis (UC) |
| Lead sponsor | Assiut University |
| Enrollment | 114 (estimated) |
| Start date | 2026-08-01 |
| Primary completion (est.) | 2027-01-31 |
| First posted | 2026-06-09 |
| Last updated | 2026-06-11 |
| Official title | Urinary Prostaglandin E-Major Metabolite (PGE-MUM) Discriminates Disease Activity in Ulcerative Colitis: A Cross-Sectional Study From Egypt |
| ClinicalTrials.gov ID | NCT07637045 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * Adult patients aged ≥18 years * Confirmed diagnosis of Ulcerative Colitis based on clinical, endoscopic, and histopathological criteria * Active disease (Mayo Endoscopic Score 2-3, Clinical Activity Index ≥4) OR remission (Mayo Endoscopic Score 0-1, Clinical Activity Index ≤3) * Willing and able to provide written informed consent Exclusion Criteria: * Patients with other types of colitis (e.g., Crohn's disease, infectious colitis, ischemic colitis) * History of colectomy * Current smokers * Chronic lung disease * Malignancy * Use of laxatives or NSAIDs within 2 weeks prior to enrollment * Chronic kidney disease * Pregnancy or lactation * Active infection
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Rajhi University Hospital | Asyut | Egypt |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.